Clinical Trials – Indianapolis Business Journal

Home » Clinical Trials

Med school enrolls first U.S. patient in global trial to treat childhood chronic kidney disease

July 22, 2026

If chronic kidney disease progression is not slowed, patients eventually face being put on dialysis or may require a kidney transplant.

0Comments

Obesity drug trials complicated by placebo patients leaving early

March 23, 2026

Bloomberg News

The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.

4Comments

Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity

July 31, 2025 | Bloomberg News

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results showed enough cardio benefits to eventually encourage investors.

FDA to offer faster drug reviews to companies promoting ‘national priorities’

June 17, 2025 | Associated Press

Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.

Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot

April 17, 2025 | Bloomberg News

Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug

December 4, 2024 |

John Russell

Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.

Lilly weight-loss drug shows promise as a sleep apnea treatment in late-stage trials

April 17, 2024 | IBJ Staff

Meanwhile, demand for Lilly’s Zephound and Mounjaro is leading to a shortage of the drugs that is expected to last until at least mid-year, the FDA said in an update Wednesday.

Carmel-based NICO Corp. hoping for big boost after clinical trial favors its stroke treatment

April 24, 2023 |

John Russell

A seven-year clinical trial concluded that NICO Corp.’s devices are safe and effective to treat intracerebral hemorrhage.

Lilly’s older Alzheimer’s drug fails to prevent disease in trial

March 8, 2023 |

John Russell

Eli Lilly said the study concludes its clinical development of solanezumab, apparently shutting the door on one of the most closely watched experimental drugs over the past decade.

FDA approves Lilly diabetes drug that helps patients lose weight

May 13, 2022 |

John Russell

The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.

Lilly’s new weight-loss drug is a ‘double wow’ and likely blockbuster

May 6, 2022 |

John Russell

The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.

Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline

January 11, 2021 |

John Russell

The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.

Eli Lilly says other antibody trials ongoing after pause in one study

October 14, 2020 | Bloomberg News

Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.

Opioid alternative from Lilly, Pfizer shows promise in study

October 24, 2018

The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.

New Lilly R&D chief planning blitz of drug launches

July 12, 2018

Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.

Trial of potential Alzheimer’s treatment shows rare positive results

July 6, 2018

While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.

Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests

June 12, 2018

An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.

In setback for Lilly, FDA limits dosage, slaps warning on new arthritis drug

June 1, 2018

The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.

Assembly Biosciences’ market value surges to nearly $1B, despite red ink

December 14, 2017

The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.

FDA aims to expand early-approval program for promising drugs

November 30, 2017

The Food and Drug Administration wants to help patients get faster access to promising cancer treatments, FDA Commissioner Scott Gottlieb told House lawmakers Thursday.

Lilly shares rise on surprising news from FDA on arthritis drug

August 30, 2017

The Indianapolis drugmaker said it will not be required to conduct another expensive, time-consuming clinical trial for the potential blockbuster.

Lilly, Pfizer get boost for non-opioid pain drug

June 23, 2017

The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.

JULY 24-30, 2026

Digital Edition

What do these Indiana 250 leaders have in common? A paper route!

Lesley Weidenbener and Ann Finch

Couple’s family experience spurs app for caregivers

Daniel Bradley

Q&A: Father’s advice, brother’s example help shape unlikely construction career

Lesley Weidenbener

Previous Issues See Full Issue

Events

IBJ will honor Indiana nonprofits, foundations, organization leaders, businesses who work with nonprofits and philanthropists at the inaugural Nonprofit Excellence Awards presented by KSM CPA & Advisors.

RSVP HERE!

More events

Nominations

IBJ will spotlight some of our city’s most successful business women from both the public and private sectors while revealing the triumphs and challenges that have shaped their careers.

NOMINATE HERE!

Join us for Indy’s premier business executive event as we celebrate leadership at the highest level. Be there as we unveil the CEO of the Year and honor exceptional achievements across the C-Suite. From CMOs driving groundbreaking marketing strategies to CTOs spearheading cutting-edge technology, this exclusive awards event showcases the very best in the business.

NOMINATE HERE!